Sagent Pharmaceuticals — Schaumburg

Sagent Pharmaceuticals has initiated a Class III recall of 9,528 vials of Busulfan Injection (NDC 25021-241-10) nationwide due to failed impurities and degradation specifications. This marks Sagent's second significant recall in two years, following a 2024 event for Methylprednisolone Acetate. Procurement and regulatory teams must assess supply chain stability for Busulfan, an oncology drug, and evaluate alternative suppliers to mitigate potential disruptions.